August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) Occluder FDA IDE trial showed the Amulet was superior for the primary endpoint of LAA closure and noninferior for the primary endpoints of safety and effectiveness versus the first generation Boston Scientific Watchman occluder. A new version of the Watchman was released in 2020 and was not part of this trial.
The transcatheter occluders are used to permanently seal the LAA to treat patients with atrial fibrillation (AFib) at an increased risk of stroke. The Amulet recently entered the U.S. market and became the first competitor of the Watchman.
The findings were presented Monday in a late-breaking Hot Line session at European Society of Cardiology (ESC) Congress 2021, and simultaneously published in Circulation. The trial results also supported the recent U.S. approval of Amulet.
"Atrial fibrillation cases have increased in recent years as the world continues to age, making stroke risk more prevalent and resulting in higher usage of blood-thinning medication that can lead to bleeding and other complications," said Dhanunjaya Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health, who served as principal investigator for the study. "Amulet demonstrated a clear benefit for people suffering from atrial fibrillation who are at risk of stroke and in need of LAA occlusion. The Amulet IDE trial data show that we can effectively treat these patients with Amulet and get them off blood thinners immediately following implantation."
Clinical Evidence Presented for Amulet at ESC
The Amulet IDE trial is the first multicenter, large-scale randomized study to compare Abbott's Amulet device head-to-head with the Watchman device.
Results from the study demonstrated that Abbott's Amulet Occluder with Dual-Seal technology:
- • Was successfully implanted in 98.4% of patients compared to 96.4% of patients receiving the Watchman device.
- • Demonstrated superiority for the primary endpoint of LAA closure compared to Watchman (98.9% vs. 96.8%, p (superiority) = 0.0025).
- • Was noninferior to the comparator device for the co-primary safety endpoint (a composite of procedure-related complications, all-cause death or major bleeding through 12 months) and co-primary effectiveness endpoint (a composite of ischemic stroke or systemic embolism through 18 months).
Importantly for patients and their physicians, Amulet did not require the use of blood thinners for participants following implant in the study. Watchman patients were mostly (82%) discharged on anticoagulant therapy (warfarin plus aspirin). In contrast, only 20% of Amulet patients were discharged on anticoagulants, and most (75.7%) were discharged on dual antiplatelet therapy (clopidogrel plus aspirin).
"Now backed by the strength of the Amulet IDE data and the ability to immediately close the LAA, our Amulet device has the potential to change the way physicians approach LAA occlusion therapy," said Michael Dale, senior vice president of Abbott's structural heart business. "Offering immediate, superior LAA closure allows Americans living with atrial fibrillation to experience greater peace of mind against the worry of having a stroke without the need for blood-thinning medication immediately following the procedure."
The Amplatzer Amulet LAA Occluder has been approved for use in more than 80 countries, including in Europe, Canada and Australia, since its initial CE Mark approval in 2013. Amulet is part of the Abbott Amplatzer family of products with proven clinical success for more than two decades.
Amulet IDE Trial Used Older Generation Watchman Device
The Amulet IDE trial was a head-to-head comparison with the legacy Watchman 2.5 device, which is no longer offered for sale in the U.S. Boston Scientific released the next-generation Watchman FLX device in July 2020. Boston Scientific made modifications to the Watchman design to better anchor it in the LAA and prevent embolization.
Boston Scientific said the comparison in the Amulet trial was with the older technology, not the newer generation Watchman, which the vendor said has produced strong clinical results.
The Watchman PINNACLE FLX trial data reported in 2020 showed:
• 0.5% rate of major procedural complications
• 0% pericardial effusions
• 0% device embolization
• 100% effective LAA closure
• 99% procedural success
• 35% reduction in procedure time vs. WM 2.5
Transcatheter Occlusion of the LAA
The LAA is a small pouch connected to the upper left chamber of the heart. For people with AFib, the heart's ability to effectively pump blood can be disrupted, allowing blood to pool and collect in the LAA causing an increased risk for clotting. If clots reach the blood stream, they can travel to the brain and cause a stroke. Abbott's Amulet device with Dual-Seal technology (a lobe to fill the body of the LAA and a disc to close off the opening into the LAA) offers immediate closure of the LAA, reducing the risk of stroke and – unlike the study comparator device – immediately eliminates the need for blood-thinning medication following implant. Amulet Occluder also offers a wider range of sizes to help physicians treat a broad range of patients and allows recapturing and repositioning to ensure optimal placement.
For U.S. important safety information on Amulet, visit: https://abbo.tt/AmuletISI.
Related LAA Occlusion Content:
FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation
VIDEO: Overview of LAA Occlusion Using the Watchman FLX —Interview with Devi Nair, M.D.
FDA Clears Next-generation Watchman FLX Left Atrial Appendage Occlude
Occluding the Left Atrial Appendage (LAA)
VIDEO: Comparison Between Watchman vs. Amulet LAA Occluders — Interview with Ashish Pershad, M.D.
First-Of-Its-Kind, No-Implant LAA Occluder Noted for Innovation at 2019 ICI Meeting
VIDEO: Overview of Left Atrial Appendage (LAA) Closure Technology and New Innovations — Interview with Horst Sievert, M.D.
Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial